COVID-19 Clinical Trial
— OPTICOVOfficial title:
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the OPTICOV Study
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.
Status | Recruiting |
Enrollment | 256 |
Est. completion date | May 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: 1. Laboratory confirmed SARS-CoV-2 infection by RT-PCR or positive antigenic test 2. Asymptomatic or mild to moderate COVID-19 (WHO progression scale <5). Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible) 3. = 16 years of age; 4. Immunocompromised as defined by = 1 risk factors for severe COVID-19 as assessed by the FOPH list (criteria 5: diseases/treatments leading to immune suppression) - Severe immunosuppression (e.g., HIV infection with CD4 + T cell count <350 / µl) - Neutropenia (<1000 neutrophils / µl) =1 week - Lymphocytopenia (<200 lymphocytes/µl) - Hereditary immunodeficiencies - Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, everolimus, mTOR inhibitors etc.) in the last 12 months - Active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib - Aggressive lymphomas (all types) - Acute lymphatic leukemia - Acute myeloid leukemia - Acute promyelocytic leukemia - T prolymphocytic leukemia - Primary central nervous system lymphoma - Stem cell transplantation - Light chain amyloidosis - Chronic lymphoid leukemia - Multiple myeloma - Sickle cell disease - Bone marrow transplant - Organ transplant - Being on the waiting list for an organ transplant 5. Willing and able to comply with study requirements and restrictions as described in the informed consent form (ICF) 6. Enrolled in or a beneficiary of a Social Security program (State Medical Aid (AME) is not a Social Security program) or holders of health insurance 7. Participant's or its legal representative's signature of the informed consent form Exclusion Criteria: 1. SARS-CoV-2 PCR =30 CT at screening 2. Hypersensitivity to study drugs (active substance(s) or excipients) 3. Body weight < 40 kg 4. AST or ALT > 5 times the upper limit 5. Cirrhosis Child-Pugh score C 6. Is taking or is anticipated to require any prohibited therapies* 7. Participation in another interventional clinical study through Day 28 with an investigational compound or device, including COVID-19 therapeutics, where the study intervention is performed in the 28 days preceding the inclusion and the 10 days after the inclusion. Investigators of the different clinical studies should agree on participant's inclusion 8. Presence of any condition for which, in the opinion of the investigator, participation would not be in participant's best interest or that could prevent, limit, or confound the protocol-specified assessments 9. Having received antiviral treatments against SARS-CoV-2 in the 14 days before the inclusion with exception of those having received one or two doses of nirmatrevir/r in the 24h preceding the inclusion in the study. 10. Pregnant or breastfeeding female - Study SOPs based on recommendations from the Liverpool COVID-19 interactions, French Society for Pharmacology and Therapeutics and French Speaking Transplantation society will be provided to guide investigators |
Country | Name | City | State |
---|---|---|---|
France | Pellegrin Hospital | Bordeaux | |
France | Saint-André Hospital | Bordeaux | |
France | Francois Mitterrand Hospital | Dijon | |
France | Croix Rousse Hospital | Lyon | |
France | La Colombière Hospital | Montpellier | |
France | Hotel Dieu Hospital | Nantes | |
France | Bichat Claude-Bernard Hospital | Paris | |
France | Laribosière Hospital | Paris | |
France | Pitié-Salpêtrière Hospital | Paris | |
France | Saint Antoine Hospital | Paris | |
France | Saint Louis Hospital | Paris | |
France | Robert Debré Hospital | Reims | |
France | Purpan Hospital | Toulouse | |
France | Tourcoing Hospital | Tourcoing | |
Switzerland | Basel University Hospital | Basel | |
Switzerland | University Hospitals of Geneva | Geneva | |
Switzerland | University Hospital CHUV | Lausanne | |
Switzerland | University Hospital Zurich | Zürich |
Lead Sponsor | Collaborator |
---|---|
ANRS, Emerging Infectious Diseases | University Hospital, Geneva |
France, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients with SARS-CoV-2 viral load (threshold cicle (Ct) <32) by real-time RT-PCR in nasopharyngeal swabs at Day 10 after treatment initiation. | SARS-CoV-2 viral load is measured in nasopharyngeal swabs by real-time RT-PCR | Day 10 | |
Secondary | Percentage of patients with SARS-CoV-2 viral load (threshold cicle <32 CT) by real-time RT-PCR in nasopharyngeal swabs at Day5, Day14 and Day21 after treatment initiation | SARS-CoV-2 viral load is measured in nasopharyngeal swabs by real-time RT-PCR | Day5, Day14 and Day21 | |
Secondary | Percentage of patients with detectable SARS-CoV-2 viremia at Day5, Day10 and Day14 | SARS-CoV-2 viremia is measured from plasma samples by real-time RT-PCR | Assessed for 14 days from the date of randomisation at Day5, Day10 and Day14 | |
Secondary | Decrease of SARS-CoV-2 viral load measured by copies/ml by nasopharyngeal swab at Day5, Day10, Day14, Day21 and in blood samples at Day5, Day10 and Day14 comparatively to screening | SARS-CoV-2 viral load is measured in nasopharyngeal swabs and in blood samples by real-time RT-PCR | Day5, Day10, Day14, Day21 | |
Secondary | Number of de novo emergence of mutations on nasopharyngeal RT-PCR at Day5, Day10, Day14 and Day21 comparatively to screening | Emergence of mutations is measured in nasopharyngeal swabs by genotyping techniques | Day5, Day10, Day14 and Day21 | |
Secondary | Time to first negative SARS-CoV-2 RT-PCR (CT<32) until Day90 | SARS-CoV-2 viral load is measured in nasopharyngeal swabs by real-time RT-PCR | Day90 | |
Secondary | Absence of ability to cultivate virus from viral cultures from nasopharyngeal swabs at Day5, Day10 and Day21 | Viral culture is performed from nasopharyngeal swabs samples | Day5, Day10 and Day21 | |
Secondary | Percentage of patients with sustained resolution or abatement of symptoms defined as a FLU-PRO-Plus score =1 at Day5, Day10, Day14, Day21 and Day28 | FLU-PRO-Plus score is measured via an arithmetic formula | Day5, Day10, Day14, Day21 and Day28 | |
Secondary | All-cause hospitalization and/or death at Day28 | Outcome measured during patients medical follow-up | Day28 | |
Secondary | Hospitalization at Day28 | Outcome measured during patients medical follow-up | Day28 | |
Secondary | Death at Day28 | Outcome measured during patients medical follow-up | Day28 | |
Secondary | Rate of Post-COVID19 condition at Day90 according to the WHO October 2021 definition | Rate of Post-COVID19 condition at Day90 according to the WHO October 2021 definition:
o Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time. |
Day 90 | |
Secondary | Percentage of participants with an adverse event (AE) or serious adverse event (SAE) or AE leading to treatment discontinuation up to Day28 | Outcome measured during patients medical follow-up | Day 28 | |
Secondary | Adherence to nirmatrelvir/r with patient-reported adherence and nirmatrelvir/r residual plasma dosage at Day5 and Day10 | Outcome measured by patient-reported adherence and drug residual dosage using dried spot (DBS) | Day5 and Day10 | |
Secondary | Number of DDIs who led to dosage adjustment of other patient's drugs | Outcome measured during patients medical follow-up | Assessed up to Day 10 from randomisation | |
Secondary | Percentage of patients with specific retreatment patients (by antiviral antiinflammatory drugs or convalescent plasma through Day90 | Outcome measured during patients medical follow-up | Day90 | |
Secondary | To assess the phenotypic resistance (IC50 increase) against treatment for viral strains cultured from nasopharyngeal swabs | Outcome measured in nasopharyngeal swabs by phenotyping techniques | Day5, Day10, Day14, Day21 | |
Secondary | Immunosuppressors residual concentrations, if applicable | Outcome measures in participants' blood samples | as needed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|